

Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study

Bruno Fattizzo,¹ Marc Michel,^{2,3} Anna Zaninoni,¹ Juri A. Giannotta,¹ Stephanie Guillet,^{2,3} Henrik Frederiksen,⁴ Josephine M.I. Vos,⁵ Francesca R. Mauro,⁶ Bernd Jilma,⁷ Andrea Patriarca,⁸ Francesco Zaja,⁹ Anita Hill,¹⁰ Sigbjørn Berentsen¹¹ and Wilma Barcellini¹


¹Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano and University of Milan, Milan, Italy; ²Department of Internal Medicine, Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Creteil, France; ³Internal Medicine, National Reference Center for Adult Immune Cytopenias, Henri Mondor University Hospital, Université Paris-Est Créteil, France; ⁴Department of Haematology, Odense University Hospital, Odense, Denmark; ⁵Amsterdam UMC, Location AMC, Department of Hematology, Amsterdam, the Netherlands; ⁶Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy; ⁷Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria; ⁸UO Ematologia, AOU Maggiore della Carità, Novara, Italy; ⁹S.C. Ematologia, Azienda Sanitaria Universitaria Integrata, Trieste, ITA; ¹⁰Hematology, Leeds Teaching Hospitals, Leeds, UK and ¹¹Department of Research and Innovation, Haugesund Hospital, Haugesund, Norway

Correspondence: WILMA BARCELLINI - wilma.barcellini@policlinico.mi.it

doi:10.3324/haematol.2020.250522

Figure 1S

Maximal hemoglobin increase from baseline after erythropoietin treatment



Panel A: individual maximal Hb increase from baseline according to autoimmune hemolytic anemia type (wAIHA warm autoimmune hemolytic anemia; wAIHA+C warm autoimmune hemolytic anemia with complement positivity; CAD cold agglutinin disease; DAT neg direct antiglobulin test negative).

Panel B: individual maximal Hb increase from baseline according to number of previous therapy lines.